Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 ビュー
• 07/02/23
0
0
埋め込む
administrator
加入者
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント